|
NEK4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.10702591327572E-14 |
| Normal-vs-Stage2 |
2.42239999999061E-05 |
| Normal-vs-Stage3 |
1.17794662912729E-13 |
| Normal-vs-Stage4 |
6.99884594723699E-13 |
| Stage1-vs-Stage2 |
1.197390E-01 |
| Stage1-vs-Stage3 |
6.741600E-02 |
| Stage1-vs-Stage4 |
9.801500E-03 |
| Stage2-vs-Stage3 |
1.055970E-02 |
| Stage2-vs-Stage4 |
2.498100E-03 |
| Stage3-vs-Stage4 |
4.517600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
3.66379999999777E-05 |
| Normal-vs-Asian |
1.38800004823025E-09 |
| Caucasian-vs-AfricanAmerican |
4.989800E-01 |
| Caucasian-vs-Asian |
8.600000E-01 |
| AfricanAmerican-vs-Asian |
4.552200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.88418203051333E-15 |
| Normal-vs-Female |
1.64457336637724E-12 |
| Male-vs-Female |
5.460500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.96209715142004E-12 |
| Normal-vs-Age(41-60Yrs) |
1.58983937126322E-13 |
| Normal-vs-Age(61-80Yrs) |
6.39019948067698E-11 |
| Normal-vs-Age(81-100Yrs) |
2.064900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.861200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.595200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.174400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.828400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.610000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.391200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.235800E-02 |
| Classical-VS-Follicular |
5.073900E-02 |
| Classical-VS-Other |
6.431200E-01 |
| Classical-VS-Normal |
2.2531998489228E-10 |
| Tall-VS-Follicular |
1.420790E-03 |
| Tall-VS-Other |
5.855600E-01 |
| Tall-VS-Normal |
1.97950544844616E-11 |
| Follicular-VS-Other |
3.278400E-01 |
| Follicular-VS-Normal |
3.38050000003864E-06 |
| Other-VS-Normal |
2.059500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.53581616710608E-12 |
| Normal-vs-N1 |
9.3780538890087E-13 |
| N0-vs-N1 |
1.585510E-02 |
|
|
